{"entity":{"id":"nct05120596","kind":"trial","name":"First in Human Study of T3P-Y058-739 (T3P)","aka":[],"tldr":"A phase 1/2 trial of Pembrolizumab in advanced solid tumours, run by T3 Pharmaceuticals AG, now recruiting.","summary":"First in Human Study of T3P-Y058-739 (T3P) is a phase 1/2 interventional study registered as NCT05120596 by T3 Pharmaceuticals AG, with 100 participants planned, started 2022-04-26 and due to reach its primary completion in 2027-02-28. Interventions recorded: Pembrolizumab+T3P-Y058-739, T3P-Y058-739 (IV) and T3P-Y058-739 (IT).","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05120596","url":"https://clinicaltrials.gov/study/NCT05120596"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05120596","phase":"1/2","setting":"An Open-label, Phase I/II Study of T3P-Y058-739, a Genetically-modified Strain of the Bacterium Yersinia Enterocolitica, in Patients With Advanced Solid Tumours","sponsor":"T3 Pharmaceuticals AG","enrolled":100,"outcomes":[]},"route":"/trials/nct05120596/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}]}}